According to the Complaint, Geron Corporation is a biopharmaceutical company with its headquarters located in Menlo Park, California.

The Complaint alleges that throughout the Class Period, Defendants misled investors regarding a drug called imetelstat, which was intended to treat certain cancers that occur in bone marrow. Specifically, the Complaint alleges that Defendants: (1) misled investors about the results of a clinical drug study of imetelstat called IMbark; and (2) as a result, Defendants' statements about Geron's business, operations, and prospects were materially false and misleading and lacked a reasonable basis at all relevant times.

On May 14, 2020, the Court issued an Order consolidating cases and appointing Lead Plaintiffs. All future docketing was ordered to be done in the lead case 20-CV-00547.

On July 27, 2020, the Court approved Lead Plaintiffs' Selection of Counsel. Lead Plaintiffs filed a consolidated Complaint on August 20. On October 22, Lead Plaintiffs filed an amended consolidated Complaint. Defendants filed a Motion to Dismiss the amended consolidated Complaint on November 23. On April 12, 2021, the Court issued an Order granting in part and denying in part Defendants' Motion to Dismiss.

Lead Plaintiff filed a Motion for Class Certification on September 30, 2021. On April 2, 2022, the Court issued an Order granting the Motion for Class Certification.

On August 12, 2022, the parties notified the Court that they had reached an agreement in principle to Settle. On September 2, the parties entered into a Stipulation and Agreement of Settlement. The Court granted preliminary approval of the Settlement on October 13. On September 28, 2023, the Court issued an Order granting final approval of the Settlement, including an award of Attorneys’ Fees and Expenses. The Court entered Final Judgment on October 3.

On May 28, 2024, the Court issued an Order approving the Settlement's distribution plan.